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inappropriate use in 7%-46% of patients. The analysis was limited to drug prescrip-
tion costs and excluded other costs affected by the recommendations, resulting in 
forecasted savings ranging from $7-$16 million over a 3-year period. JSS Medical 
Research performed the BIA from the ministry of health perspective. Methods: 
Our hybrid epidemiological and claims-based BIA included costs of TRTs and key 
cost drivers of physician visits, administering injectable TRTs, testosterone level 
testing and Exceptional Access Program evaluation and processing. Ontario pre-
scription drug expenditures based on claims data, as well as published literature 
and expert opinion were utilized. We evaluated the impact of the ODPRN scenarios 
with and without inappropriate TRT use over a 3-year period. Results: Based on 
the JSS assumption of all patients qualifying for TRT and taking into consideration 
key cost drivers, option B would cost $1.01 million; option C $766,000, and option D 
$252,000. Using ODPRN assumptions of inappropriate use, JSS forecasted savings 
of $373,000-$13.4 million as opposed to savings of $7-$16 million forecasted by 
the ODPRN. ConClusions: ODPRN savings exclude key cost drivers and assume 
a greater magnitude of inappropriate use. The burden of the policy change could 
completely offset savings and generate costs of up to $1 million to the healthcare 
budget. Healthcare policy recommendations based on drug costs alone underesti-
mate the true cost, shifting and in this case creating additional costs to other areas 
of the healthcare system.
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objeCtives: Treatment guidelines propose stepwise approach for type II diabe-
tes management: metformin (Met) as first, Met + SUs or other oral antidiabetic 
agents (i.e. DPP4s) or insulin as second or third line. Despite this evidence based 
line treatment, DPP4s prescriptions in Turkey can be initiated only by endocrinol-
ogy or internal medicine specialists working on tertiary care since March 2010 to 
control DM treatment budget. This access restriction may naturally cause prescrip-
tion shifts to non-restricted treatment options such as insulins. This research’s 
objective is comparing yearly usage ratio of insulins and DPP4s in Turkey and 5 
European Turkey’s price reference countries. Methods: Sales as international 
units(IU) and value between 2010-2014 are obtained from IMS Dataview7. Yearly 
total insulin vs. DPP4s as IU/SU and US$ sales is compared between Turkey and 
France, Greece, Italy, Portugal, Spain. Results: Insulin to DPP4s utilization ratio 
in Turkey(183) is 4,6 times higher than reference countries’ average (40) in 2014. 
Compared to 5 EU countries, total insulin to DPP4s utilization ratio is consist-
ently the highest (540 in 2010 and 183 in 2014) in Turkey between 2010-2014. As 
value sales, the highest ratio of total insulin to DPP4s is in Turkey (7,2), followed 
by Italy(2,9) and France(1,3). In Portugal, Spain and Greece this ratio is below one, 
indicating higher DPP4 value sales compared to insulins. Reversed ratio of insulin 
to DPP4s in Turkey is also present between 2010-2013. ConClusions: Turkey has 
the highest insulin to DPP4 ratio over five years among other countries. DPP4s 
access restriction might have caused early and disproportionate insulinization 
of patients. From health policy perspective, implementation of access restriction 
might have led cost reduction in the short run, however it may cause greater 
burden due to shifts to later treatment lines.
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objeCtives: Diabetes is a chronic condition for which effective medications must 
be taken continuously (i.e. patient must be observant). Research shows that intro-
ducing user fees may reduce patient observance. However, there is little evidence 
that providing free medications improves diabetic patient observance. Taking advan-
tage of a change in Quebec (Canada) policy the objective of this study was to assess 
whether the return to free medications (RFM) improved diabetic patient obser-
vance. Methods: This study used a pretest-posttest design: drug use by diabetic 
patients in the 3 years prior to RFM was compared to their drug use in the 2 years 
following RFM. Data came from the Quebec public drug plan (QPDP) for three groups: 
social welfare recipients, elderly receiving full guaranteed revenue supplement (GRS) 
and those receiving partial GRS. Data on oral antidiabetic drug consumption were 
obtained for a random sample of patients that were covered by the QPDP during the 
full five year period (N total = 3308). Two indicators of observance were measured: 
whether a patient was using antidiabetic drugs at least 80% of days and the propor-
tion of days where antidiabetic drugs were used. These were measured both for the 
12 months following the first prescription prior to RFM and after RFM and for the 
whole pre-RFM and post-RFM periods. To compare pre and post RFM data, we used 
Chi-square test for the first indicator and t-test for the second indicator. Results: 
The proportion of patients who were observant was significantly (p< 0.001) higher 
after RFM compared to before RFM, both for 12 months (87.3% vs. 82.8%) and the 
whole period (85.3% vs. 83.7%). The proportion of days where antidiabetic drugs were 
used also was significantly higher (92.3% vs. 89.2%; 90.8% vs 86.6%). ConClusions: 
Providing free medications to diabetic patients raised their observance and may 
have improved patient outcomes.
PDB121
QuAntifying the efficAcy-effectiveness-gAP using the exAmPle of 
metfoRmin
Jäger A1, Amler N1, Bierbaum M2, Schöffski O1
1Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany, 2Hochschule Aalen - 
Technik und Wirtschaft, Aalen, Germany
objeCtives: According to the literature, there is a gap between the results of clini-
cal trials (efficacy) and the effects of the same intervention in real-life (effective-
ness). Although this so-called “efficacy-effectiveness gap” is often mentioned in 
studies was intermediate (score: 17 of 28). Almost all studies examined objective 
health measures, with most indicating non-significant differences between the 
Maps™ intervention and the control group/s. Mixed results were found regarding 
the influence on HbA1c. The majority of studies reported no significant change in 
blood pressure and mixed results were found regarding other health indicators. Only 
five studies examined subjective measures and eight assessed the effects on health 
behaviors, mostly reporting non-significant or positive findings. ConClusions: 
This review provides evidence about the limited number and relatively low quality 
of studies, which examined the influence of Maps™ on health outcomes. Although 
Maps™ hold the potential to improve health outcomes, there is a need to develop 
well-designed large sample studies that enable to draw more conclusive results.
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objeCtives: Type 1 diabetes mellitus (T1DM) affects approximately 400,000 people 
in the UK, amounting to £1.8 billion in direct healthcare costs in 2012. Statistics 
from the 2012/13 national diabetes audit (NDA) suggest that 92.4% of T1DM patients 
in England fail to achieve target haemoglobin A1c (HbA1c) levels (< 48 mmol/mol 
[6.5%]). Current NICE draft guidance recognises the importance of education on 
glycaemic control; recommending courses for all T1DM patients within one year of 
diagnosis. However, only 4.1% of newly-diagnosed diabetics are offered structured 
courses such as the Dose Adjustment for Normal Eating (DAFNE). We sought to 
determine the relationship between educational course availability and uptake, 
and target HbA1c achievement. Methods: Educational course attendance data 
and HbA1c results for T1DM patients was extracted from the 2012/13 NDA for 9 
regions in England, and DAFNE centre location records for 2014 were obtained. We 
explored the relationship between educational course uptake and optimal HbA1c 
achievement in newly-diagnosed patients, and also the number of DAFNE cen-
tres against overall T1DM HbA1c achievement. Results: Newly-diagnosed T1DM 
patients consistently manage HbA1c better than the overall T1DM population. 
However, no association was found between education course uptake or the number 
of DAFNE centres per region, and optimal HbA1c achievement in newly-diagnosed 
patients. A weak positive correlation was found between the number of DAFNE 
locations, and patients in the overall T1DM population achieving optimal HbA1c 
(R2= 0.3). ConClusions: Educational courses may help T1DM patients achieve bet-
ter glycaemic control. However, uptake for courses is below current NICE draft rec-
ommendations. Increasing uptake for such courses could help improve target HbA1c 
achievement in the long-term, whilst also providing a societal benefit through cost 
savings. Examining potential socio-economic factors and their impact on course 
uptake could be investigated. More research is required into educational course 
uptake in the overall T1DM population.
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objeCtives: As the number of people with diabetes grows worldwide, it becomes 
a challenging problem for public health budgets. The objective of this study is to 
investigate and analyze the main characteristics of diabetes in Turkey. Methods: 
Claims data from Turkish Social Security Institution were collected for the diagnosed 
patients having insulin dependent (IDD) and non-insulin dependent diabetes (NIDD) 
between 2010 and 2014. Prevalence, incidence, age and gender distribution, and 
mortality figures were aggregated and analyzed in order to show how the disease is 
evolving. Results: Number of patients diagnosed with diabetes between 2010 and 
2014 totaled 3.1 million; nearly 85% with NIDD and 60% were females. On average 
645,000 new patients were added yearly. The incidence of diabetes dropped from 
0.94% to 0.76% in 2010-2014, where IDD and NIDD were 0.06% and 0.71% in 2014 
respectively. While the share of NIDD patients represented 81% in 2010, the figure 
hiked 90% in 2014. When it comes to age distribution, 46-64 age group received 
the largest share (48%) among all patients, followed by 25-45 and 65+ age groups, 
all three constituting nearly 96%. The average age of first diagnosis for male and 
female were 58.6 and 59.4 respectively, signaling that the disease is late diagnosed 
compared to other countries. In addition, 21% of females and %14 of males died 
over four-year time and average age of death was nearly the same in both diabetes 
types. ConClusions: Despite the decline in the incidence, diabetes epidemic is 
expected to grow in the future with lower mortality rates. Late diagnosis of diabe-
tes seems to be the most important problem in Turkey. Then, immediate action is 
needed for new strategies such as yearly monitoring and public education programs 
to reach out patients earlier.
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objeCtives: The Ontario Drug Policy Research Network (ODPRN) published recom-
mendations to restrict reimbursement and coverage criteria of testosterone replace-
ment therapy (TRT) in Ontario. The ODPRN’s budget impact analysis (BIA) evaluated: 
no reimbursement change (option A), restricting coverage of all forms of TRT (option 
B), restricting oral and topical forms only (option C), or restricting topical forms 
only (option D). The analysis assumed exponential growth of TRT expenditures and 
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direct and indirect healthcare costs of type 2 diabetes in Austria. Methods: A 
burden of disease study, which evaluates all kinds of disease burden, like costs, 
quality adjusted life years (QALYs) and disability adjusted life years (DALYs) lost, 
was conducted. This study uses a prevalence-based bottom-up approach and pro-
jects costs over the time horizon of one year. Data were collected via literature 
review, published list prices and hospital records. Costs from published sources 
were used from the societal perspective. The direct costs include hospital, treat-
ment and physician consultation costs. Indirect costs cover patient care giver costs 
as well as work absenteeism. Results: The average costs per year of a Diabetes 
Type 2 are 3,242.91 EUR. Inpatient care is a major contributor to costs, accounting 
for 81% of total costs while drug costs account for an average of 14%. The estimated 
total direct annual cost for all patients diagnosed with type 2 diabetes is 1.2 billion 
EUR. This represents a share of 3.3% of the country´s total healthcare expendi-
tures. The average annual indirect costs for patients with diabetes mellitus type 
2 amounts to 781 million EUR. Compared to the healthy population, the diabetes 
mellitus type 2 population have utility decrements of 251,974 QALYs. Moreover 
type 2 diabetes patients will lose 19,853 DALYs within one year. ConClusions: 
Type 2 diabetes mellitus is a common disease and the prevalence is expected to 
increase considerably in the future. The findings of this study demonstrate the 
high economic import of the disease.
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objeCtives: Although type 2 diabetes (T2DM) has been globally recognised as a 
major public health issue with substantial economic implications, its quantita-
tive impact in some geographical regions is not well documented. This study 
aimed to describe the health care resource utilisation (HCRU) associated with 
T2DM in Africa, Middle East, South Asia, Eurasia and Turkey. Methods: Cross-
sectional data from 8,156 patients recruited across four geographical regions 
(18 countries) was collected as part of the 5th wave of the IDMPS (2011–2012). 
Mean (SD) annual levels of different types of HCRU were estimated and negative 
binomial regression was undertaken to identify drivers of HCRU by region and 
country. Results: Estimated HCRU showed that patients in South Asia (n= 1,195), 
Eurasia (n= 1,843), Africa (n= 2,220) Middle East (n= 2,065) and Turkey (n= 842) expe-
rienced a mean (SD) of 0.4 (1.5), 1.7 (4.1), 0.6 (1.9), 0.3 (1.2) and 1.3 (2.7) hospitalisa-
tions annually. The mean (SD) annual number of diabetes-related inpatient days 
was 1.5 (6.8), 16.0 (30.0), 4.7 (22.7), 1.1 (6.1) and 10.8 (34.3) respectively. The mean 
(SD) annual number of sick days due to diabetes for the same regions were 4.6 
(19.7), 17.5 (35.4), 11.6 (44.4), 1.4 (6.8) and 8.0 (34.4). Presence of macrovascular 
complications was a key driver of incidence of hospitalisations [Incidence Rate 
Ratio - IRR (CI 95%)] in South Asia [3.4 (1.4–8.5)], Eurasia [1.4 (1.1–1.8)], Africa [3.9 
(2.1–7.3)], Middle East [8.9 (4.6–15.7)] and Turkey [2.9 (1.8–4.6)]. Microvascular com-
plications were associated with increased risk of hospitalisations in all regions 
with IRRs (CI 95%) of 3.5 (1.8 – 7.0), 3.4 (2.2 – 5.1), 3.7 (2.2 – 5.1), 1.7 (1.0 – 2.9) 
and 3.4 (2.2 – 5.1) respectively. ConClusions: Results of this study demon-
strate that in South Asia, Eurasia, Africa, Middle East and Turkey, development 
of micro and macrovascular complications are key drivers for economic burden 
of T2DM.
PDB126
heAlthcARe use AnD exPenDituRe foR DiABetes in BAnglADesh: A 
mAtcheD-cAse-contRol stuDy
Shariful Islam SM
Ludwig-Maximilians-Universität (LMU), Munich, Germany, Munich, Germany
objeCtives: Diabetes imposes huge social and economic impact on nations. 
However, information on the costs of treating and managing diabetes in develop-
ing countries is limited. The aim of this study was to estimate healthcare use and 
expenditure for diabetes in Bangladesh. Methods: We conducted a matched 
case-control study between January and July 2014 among 591 adults with diag-
nosed diabetes mellitus (DMs) and 591 age, sex, and residence matched persons 
without diabetes mellitus (non-DMs). We recruited DMs from consecutive patients 
and non-DMs from accompanying persons in BIHS hospital in Dhaka, Bangladesh. 
We estimated the impact of diabetes on healthcare use and expenditure by calcu-
lating ratios and differences between DMs and non-DMs and tested for statistical 
difference using t-tests. Results: DMs had two times more days of inpatient 
treatment, 1.3 times more outpatient visits, and 9.7 times more medications 
than non-DMs (all p< 0.005). The total annual per capita expenditure on medical 
care was 6.12 times higher for DMs than non-DMs (USD 635 vs. 104, respectively). 
Among DMs, 9.8% reported not taking any antidiabetic medications, 46.4% took 
metformin, 38.7% sulphonylurea, 40.8% insulin, 38.7% any antihypertensive medi-
cation, and 14.2% took anti-lipids over the preceding 3 months. ConClusions: 
Diabetes significantly increases healthcare use and expenditure and is likely to 
impose a huge economic burden on the healthcare systems in Bangladesh. The 
study highlights the importance of prevention and optimum management of dia-
betes in Bangladesh, and other developing countries, to gain a strong economic 
incentive through implementing multi-sectoral approach and cost-effective pre-
vention strategies.
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literature, there is little if any attempt to quantify it. We aim to quantify the dif-
ference between the efficacy and effectiveness of Metformin in terms of reduc-
ing HbA1c in patients with type-2-diabetes. Methods: First, a systematic review 
was carried out to identify relevant randomized controlled trials (RCTs) and non-
interventional studies (NIS). CENTRAL, MEDLINE (via PubMed) and clinicaltrials.
gov were searched for relevant articles published within the last 20 years. RCTs 
and NIS which evaluated the treatment effects of Metformin in adult patients with 
type-2-diabetes and analyzed glycaemic control by means of change in HbA1c value 
were included. Studies in which Metformin was used as a concomitant antidia-
betic, studies with a study period of less than three months and studies analyzing 
subpopulations were excluded from further research. Only German and English 
papers were eligible. Second, mean values of HbA1c reduction were aggregated in 
a meta-analysis using a random-effects model. Study heterogeneity was assessed 
by the I2-parameter. To test for publication bias we used funnel plots. Results: In 
total 1151 articles were identified. 21 RCTS and 6 NIS were included in the quantita-
tive analysis. Overall HbA1c was reduced by 1.012% (95%-CI: -1.186%; -0.839%). I2 
was 99.911% (RCTs: 99.932; NIS: 97.769) indicating high heterogeneity. The compari-
son of the two settings resulted in a small difference of 0.130% in HbA1c decrease 
between RCTs (-0.953%; 95%CI: -1.188%, -0.717%) and NIS (-1.083%; 95% CI: -1.34%, 
-0.826%). ConClusions: The results of our analysis indicate that the often-men-
tioned gap between clinical studies and real-world application does not exist in the 
treatment of type-2-diabetes with Metformin.
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objeCtives: According to the National Unified Clinical Protocol of Primary and 
Secondary (Specialized) Medical Care, for type 2 diabetes mellitus preparations of 
alpha-lipoic acid (ALA) at high doses are recommended as a pathogenetic therapy 
of painful diabetic neuropathy. The pharmaceutical market of Ukraine proposes 
2 oral formulations of ALA preparations: standard and HRF (High Release form). 
Pharmacokinetic studies [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2] 
showed that comparing with the standard formulation HRF of ALA reduces the 
inter-individual variability in absorption by 58% thus ensuring optimal absorption 
in most patients. The objective of the study was to assess the consumption of oral 
formulations of ALA preparations in the pharmaceutical market of Ukraine and to 
conduct pharmacoeconomic evaluation. Methods: The consumption of 2 oral for-
mulations of ALA preparations was assessed in indicator DDDs/1000 inhabitants/day 
(DIDs). To conduct the pharmacoeconomic evaluation, results of pharmacokinetic 
studies were used [MMW Spezial, Münch. med. Wschr. 1999, 141: page 2]. Results: 
In 2013, the amount of consumption of ALA preparations in the pharmaceutical 
market of Ukraine was 1.79 DIDs. The portion of HR formulation accounts for 5.35% 
of the total amount of consumption and the consumption of the standard oral 
formulation of ALA preparations accounts for 94.65%, respectively. According to 
authors of the study, the indicator of the inter-individual variability in absorption 
was 22% for HRF and 59% – for standard ALA formulation. Thus NNT indicator is 
1/0.37 = 2.7. Calculating the cost of achieving a therapeutically effective plasma 
level in 1 patient on the NNT indicates that the achievement of a therapeutic level 
in the blood plasma needs 2.7 times more costs when administering the standard 
ALA formulation compared to HRF. ConClusions: HR formulation of ALA has a 
higher cost effectiveness compared to the standard oral formulation, which makes 
it more efficient to use.
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objeCtives: To assess medical technologies in order to increase efficiency and 
reduce the cost of thyroid disease treatment. Methods: We made the retrospective 
analysis of 81 patients’s medical records with hypothyroidism that were hospital-
ized to the endocrinology department of Ternopil University Hospital (Jan-Dec 2012). 
The cost of replacement therapy with levothyroxine drugs, which were preferred 
in practice, was analyzed. We also checked the appropriateness of diagnostics and 
specialist consultations according to the Protocol of medical care for patients with 
endocrine system disorders. Results: The result of retrospective analysis of 81 
patients’s medical records with hypothyroidism showed that all patients received 
replacement therapy by levothyroxine. Among them 74 patients were treated with 
drugs of Ukrainian production while 7 patients were taking medicine of foreign 
manufacturer. The cost of pharmacotherapy with foreign medicines was 125% 
more expensive compare to Ukrainian drugs. When comparing diagnostics and 
specialists consultations with a Protocol of medical care for patients with endo-
crine system disorders we have established compliance. However, given the preva-
lence of complications of underlying disease by cardiovascular system disorders 
(in 100% of patients), we consider it necessary to add cardiologist consultation to 
Protocol. ConClusions: It is advisable to use domestic drugs in pharmacotherapy 
of hypothyroidism. Cardiologist consultation should be added to Protocol of medical 
care for patients with hypothyroidism.
PDB124
BuRDen of DiseAse of DiABetes mellitus tyP-2 in AustRiA
Bauer M
Institute for Pharmaeconomic Research, Vienna, Austria
objeCtives: Type 2 diabetes mellitus affects 358,267 individuals in Austria and 
exerts a substantial economic burden on patients, healthcare systems and society. 
The main objective of this study is to analyse the burden of disease as well as the 
